Cargando…
Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway
BACKGROUND: Chemoresistance reduces the 5-year survival rate of endometrial cancer patient, which is the current major obstacle for cancer therapy. Increasing evidence state that Nrf2 contributes to chemoresistance in several kinds of cancer. However, its role in endometrial cancer cells remains unc...
Autores principales: | Liao, Hong, Zhu, Dan, Bai, Mingzhu, Chen, Huifen, Yan, Shihuan, Yu, Jing, Zhu, Huiting, Zheng, Wenxin, Fan, Guorong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541302/ https://www.ncbi.nlm.nih.gov/pubmed/33041661 http://dx.doi.org/10.1186/s12935-020-01470-x |
Ejemplares similares
-
SOX17 increases the cisplatin sensitivity of an endometrial cancer cell line
por: Zhang, Yongli, et al.
Publicado: (2016) -
Health Benefits and Pharmacological Properties of Stigmasterol
por: Bakrim, Saad, et al.
Publicado: (2022) -
Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis
por: Chang, Yue, et al.
Publicado: (2021) -
TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells
por: Wu, Xiao, et al.
Publicado: (2017) -
Advances in Stigmasterol on its anti-tumor effect and mechanism of action
por: Zhang, Xiaoyu, et al.
Publicado: (2022)